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INTRODUCTION
Aspergillus spp. are ubiquitous in the environment, includ-
ing the air, soil and decomposing material (1). Human
invasive aspergillosis arises from the inhalation and contig-
uous spread of Aspergillus to adjacent sites (e.g., petrous
bone, the sinuses, the palate). Occasionally, human invasive
aspergillosis can be the result of the direct extension or
hematogenous spread from pulmonary foci or of intravenous
drug abuse (1). Invasive aspergillosis typically occurs in
immunocompromised patients. Interestingly, some cases of
surgical wound infection have been reported in immuno-
competent individuals (1). The occurrence of post-operative
aspergillosis can be associated with the dissemination of
spores in the operating room through the ventilation system,
which can lead to the contamination of exposed tissue, the
surgical materials, the prosthesis or the wound dressing (1).
Deep bone wound infection is a severe complication of
coronary artery bypass graft (CABG) surgery. Chronic
osteomyelitis is unusual, reported in 1 to 4% of patients,
and is most frequently caused by staphylococci (2,3).
Aspergillus spp. are rare but recently recognized causes of
nosocomial chronic sternal infections, including especially
difficult-to-treat cases of osteomyelitis/costochondritis of
the sternum (1).
The optimal treatment for invasive bone aspergillosis is a
combination of surgical treatment and appropriate anti-
fungal therapy. Currently, voriconazole is being advocated
for the treatment of invasive aspergillosis (4,5). Herein, we
report an unusual and very interesting case of chronic
osteomyelitis and costochondritis caused by aspergillosis of
the chest wall following cardiac surgery in an immuno-
competent patient who was successfully treated with
vacuum-assisted closure therapy following surgical debri-
dement and voriconazole therapy.
CASE DESCRIPTION
A 59-year-old man with diabetes, hypertension, and
hypercholesterolemia who had undergone coronary angio-
plasty three and a half years earlier underwent CABG in
September 2008. The postoperative course was uneventful,
and the patient was discharged nine days after the bypass
surgery. The patient had been well until February 2009,
when progressive and intense chest pain around the sternal
wound and shoulders developed, followed by malaise and
weight loss (approximately 7 kg). One week before admis-
sion, the patient experienced purulent discharge at the
sternal wound. On evaluation, he appeared tired and
restless; his blood pressure was 1206 70 mmHg, his pulse
was 100 beats per minute, his temperature was 36.9 C˚, and
his respiratory rate was 18 breaths per minute. There was
hyperemia limited to the sternal wound; the remainder of
the examination was normal. Laboratory results at the time
of admission revealed a robust increase in plasma C-reactive
protein (181 mg/dL); hemoglobin 9.7 mg/dl; leukocytes
10800/mm3 (neutrophils 73%, lymphocytes 19%); platelets
633.000/mm3; urea 40 mg/dL; and creatinine 0.82 mg/dL.
A chest tomography scan showed no bone abnormalities.
All aerobic and anaerobic blood cultures (three samples)
were sterile, and empiric intravenous therapy with vanco-
mycin (1000 mg 12/12 hours) plus ciprofloxacin (400 mg
12/12 hours) was started. After four days, purulent wound
discharge was observed. Technetium-99 m/Gallium-67
scintillography confirmed osteomyelitis in the region of
the sternal wound.
The patient underwent aggressive surgical debridement
by thoracic and plastic surgeons with the removal of steel
stitches, which revealed bilateral infection in the 3rd to 8th
costal cartilages (Figure 1A), which were partially removed
(Figure 1B), and vacuum-assisted closure (VAC) was used.
The subject remained on VAC until new surgical debride-
ment was performed bilaterally on the 6th ribs four days
later (Figure 1C). The VAC device was removed, a
PortovacH tube was inserted, and the wound was closed
primarily (Figure 1D). The patient had a favorable clinical
evolution, without signs of systemic disseminated infection.
Cartilaginous-bone tissue biopsies from the first and second
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surgical procedures showed Aspergillus osteomyelitis. The
culture from the surgically removed sternal bone demon-
strated the presence of Aspergillus spp. Treatment with a
combination of vancomycin and ciprofloxacin was discon-
tinued, and intravenous voriconazole (4 mg/kg per dose
twice daily) was started six days after the first surgery. The
PortovacH tube was removed three days later, and the patient
was discharged on the 18th day after the first surgical
procedure. Intravenous voriconazole therapy was continued
for a total of 42 days, when it was changed to oral capsules for
4 more months. After 3 months of voriconazole therapy,
plasma C-reactive protein normalized, and Technetium-
99 m/Gallium-67 scintillography showed no evidence of
osteomyelitis. The patient currently remains very well, and
the sternal wounds have healed completely.
DISCUSSION
Invasive aspergillosis affecting bone tissue is considered
an unusual event, accounting for 1.8% to 5.6% of invasive
aspergillosis cases (4,6), and has a high mortality rate
(22.2% to 25%) (7,8). Vandecasteele et al. (7) reported that
sternal wound infections developed at a median of 14 days
after cardiac surgery in nine patients during an outbreak
of A. flavus. In contrast, our patient had an incubation
period of at least two months and experienced an insidious
course with chest pain and weight loss diagnosed as
osteomyelitis four months after the symptoms first
appeared. The lack of fever, wound inflammation, and
purulent or serous wound discharge delayed the suspicion
of surgical-site infection. Similarly long incubation times
were reported by Verghese et al. (9) (3 months) and Elahi
et al. (2 months) in Aspergillus spp. osteomyelitis case
reports (10).
Liposomal amphotericin B was considered the most
suitable clinical treatment for invasive aspergillosis until
recently (11). Another potential option is the new formulation
of oral itraconazole solution, which penetrates bone tissue
more effectively and can be used as a prolonged outpatient
treatment. Vandecasteele et al. reported a 77.7% overall cure
rate when combining itraconazole and surgical debridement,
although 42.8% of the patients had multiple relapses that
required multiple treatment courses (7). In the last few years,
voriconazole emerged as the first-line antifungal agent for the
treatment of invasive aspergillosis, based on its activity
against Aspergillus, its acceptable side-effect profile, and the
bioavailability of the oral formulation (12). The adverse
effects reported include transient visual disturbances, hepa-
totoxicity, and severe photosensitivity rash (12), which must
be taken into consideration when long courses of therapy are
required, as in the case of osteomyelitis. Most studies have
reportedmild tomoderate adverse effects, which did not lead
to the discontinuation of therapy (4,8). In a case series of 12
patients with Aspergillus spp. osteomyelitis (8), 63.6%
responded to antifungal combinations including voricona-
zole. Mouas et al. (4) reviewed the cases of 20 patients with
bone aspergillosis treated with voriconazole (in 2 cases as
first-line therapy and in 18 cases as salvage therapy because
treatment had failed or the patient did not tolerate the
previous antifungal therapy) and found that there was a
satisfactory response in 55% of patients. In this study, when
considering only immunocompetent patients, the response to
therapy increased to 83.3% (5/6). The optimal duration of
treatment for Aspergillus osteomyelitis is not known; how-
ever, a duration of several months is typically recommended
(8,10).
The treatment for invasive bone aspergillosis is based
on the combination of surgical and medical approaches.
Figure 1 - A) Bilateral infection in the 3rd to 8th costal cartilages and ribs. B) 3rd to 8th bilateral costal cartilage removal. C) Second
bilateral debridement of the 6th ribs on the 4th post-operative day. D) Final apperance of the wound with insertion of a PortovacH tube.
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Regardless of the antifungal drug used, most studies
acknowledge the importance of surgical treatment. Stratov
et al’s review (5) indicates that the rate of successful cure
among patients treated with amphotericin B was higher
when treatment was used in combination with surgery (75%
versus 14%). Aggressive surgical debridement may be
required, as shown in the current and previous reports
(10). In Elahi et al’s case (10), a similar patient underwent
four debridements, which briefly consisted of partial
resection of the sternum and the 6th, 7th, 8th, 9th, and 10th
ribs; reinforcement of the bilateral pectoralis major flaps
with omentum; and the creation of a lateral myocutaneous
flap and a triangular skin flap in combination with use of
the vacuum-assisted curative system for wound closure. In
our case, the collaboration of thoracic and plastic surgeons
was required to assure that well-vascularized defect cover-
age could be achieved through reconstruction. The retention
of small foci of osteomyelitis and costochondritis may be
considered the main reasons for the failure of surgical
debridement given the extreme vulnerability of costal
cartilage to infection, especially when denuded of perichon-
drium or devascularized due to the use of the internal
mammary artery (10).
The use of vacuum-assisted closure therapy has drama-
tically changed the treatment of complex wounds (13).
Regarding chest wounds, most algorithms recommend its
use following surgical debridement, as it allows for wound
drainage, granulation stimulation, increased tissue blood
flow, chest wall stabilization, chest cavity isolation to
prevent contamination, and the maintenance of a moist
environment (13). Consequently, the rate of reinfection
and the length of the patient’s hospital stay are decreased
(14). Soft-tissue flaps are usually used for the definitive
closure of deep sternal wounds, after vacuum-assisted
closure therapy has been employed for several days (14).
In our case, however, it was possible to perform primary
closure.
In conclusion, invasive bone aspergillosis should be
considered when dealing with slowly progressive chest
wall wound infections following cardiac surgery, even in
immunocompetent patients. It is increasingly accepted that
voriconazole may be the drug of choice for the treatment of
Aspergillus osteomyelitis, and aggressive surgical debride-
ment is recommended to improve the rate of treatment
success.
AUTHOR CONTRIBUTIONS
Siciliano RF, Waisberg DR, Samano MN, Leite PF, Tuma Ju´nior P and
Barreiro GC contributed to data collection and manuscript preparation.
Strabelli TM performed critical revision of the manuscript.
REFERENCES
1. Pasqualotto A, Denning D. Post-operative aspergillosis. Clin Microbiol
Infect. 2006;12:1060-76, http://dx.doi.org/10.1111/j.1469-0691.2006.01512.x.
2. Zacharias A. Habib RH. Factors predisposing to median sternotomy
complications. Deep vs superficial infection. Chest. 1996;110:1173–8,
http://dx.doi.org/10.1378/chest.110.5.1173.
3. Parisian Mediastinitis Study Group. Risk factor for deep sternal wound
infection after sternotomy: a prospective, multicenter study. J Thorac
Cardiovasc Surg. 1996;111:1200-7, http://dx.doi.org/10.1016/S0022-
5223(96)70222-2.
4. Mouas H, Lutsar I, Dupont B, Fain O, Herbrecht R, Lescure F, et al.
Voriconazole for invasive bone aspergillosis: a worldwide experience of
20 cases. Clin Infect Dis. 2005;40:1141-47, http://dx.doi.org/10.1086/
428734.
5. Stratov I, Korman T, Johnson P. Management of Aspergillus osteomye-
litis: report of failure of liposomal amphotericin B and response to
voriconazole in an immunocompetent host and literature review.
Eur J Clin Microbiol Infect Dis. 2003;22:277-83.
6. Denning D, Stevens D. Antifungal and surgical treatment of invasive
aspergillosis: review of 2,121 published cases. Rev Infect Dis
1990;12:1147-201, http://dx.doi.org/10.1093/clinids/12.6.1147.
7. Vandecasteele S, Boelaert J, Verrelst P, Graulus E, Gordts B. Diagnosis
and treatment of Aspergillus flavus sternal wound infections after
cardiac surgery. Clin Infect Dis. 2002;35:887-90, http://dx.doi.org/
10.1086/342699.
8. Horn D, Sae-Tia S, Neofytos D. Aspergillus osteomyelitis: review of 12
cases identified by the Prospective Antifungal Therapy Alliance registry.
Diagn Microbiol Infect Dis. 2009;63:384-87, http://dx.doi.org/10.1016/
j.diagmicrobio.2008.12.005.
9. Verghese S, Chellamma T, Cherian K. Osteomyelitis of the rib caused by
Aspergillus flavus following cardiac surgery. Mycoses. 2009;52:91-93,
http://dx.doi.org/10.1111/j.1439-0507.2008.01541.x.
10. Elahi M, Mitra A, Spears J, McClurken J. Recalcitrant chest wall
Aspergillus fumigatus osteomyelitis after coronary artery bypass grafting:
successful radical surgical and medical management. Ann Thorac Surg.
2005;79:1057-59, http://dx.doi.org/10.1016/j.athoracsur.2003.09.119.
11. Stevens D, Kan V, Judson M, Morrison V, Dummer S, Denning D, et al.
Practice guidelines for diseases caused by Aspergillus. Infectious
Diseases Society of America. Clin Infect Dis. 2000;30:696-709, http://
dx.doi.org/10.1086/313756.
12. Walsh T, Anaissie E, Denning D, Herbrecht R, Kontoyiannis D, Marr K,
et al. Treatment of aspergillosis: clinical practice guidelines of the
Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327-60,
http://dx.doi.org/10.1086/525258.
13. Orgill DP, Bayer LR. Update on Negative-Pressure Wound Therapy.
Plast Reconstr Surg. 2011;127:105S-115S, http://dx.doi.org/10.1097/
PRS.0b013e318200a427.
14. Cowan KN, Teague L, Sue SC, Mahoney JL. Vacuum-assisted wound
closure of deep sternal infections in high-risk patients after cardiac
surgery. Ann Thorac Surg. 2005;80:2205–12, http://dx.doi.org/10.1016/
j.athoracsur.2005.04.005.
CLINICS 2012;67(3):297-299 Poststernotomy Aspergillosis
Siciliano RF et al.
299
